Brad Smith joined Sullivan & Cromwell immediately after completing law school. Over the last 25+ years, his practice has covered a wide range of litigation and counseling, with emphasis on antitrust and financial services matters. Brad’s antitrust work includes some of the largest and most high profile matters on record: United States v. Microsoft (1998-2004), InBev’s $52 billion acquisition of Anheuser-Busch (2008), Bayer’s $66 billion acquisition of Monsanto (2016-2018), and Pfizer’s $43 billion acquisition of Seagen (2023). He currently oversees all pre-merger notifications under the Hart-Scott-Rodino Act and provides substantive antitrust advice to clients in both merger and non-merger cases. Altogether, he has represented technology, life sciences, financial services, transportation and industrial clients in dozens of M&A transactions collectively valued at over $500 billion.